Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biotime Inc (NY: BTX )

0.9199 USD UNCHANGED
Last Price Updated: 8:00 PM EDT, Aug 9, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Biotime Inc

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, reported financial and operating results for the second... 
From Business Wire News Releases
BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it will report its second quarter 2019... 
From Business Wire News Releases
BioTime Announces Name Change to Lineage Cell Therapeutics
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is launching a new corporate brand,... 
From Business Wire News Releases
Commit To Purchase BioTime At $1, Earn 34.6% Annualized Using Options
Investors considering a purchase of BioTime Inc (BTX) stock, but tentative about paying the going market price of $1.17/share, might benefit from considering selling puts among the alternative... 
Tags Stocks
From Market News Video
BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has dosed its first patient with the... 
From Business Wire News Releases
Tesla, Unum Therapeutics Making Big Moves In Tuesday's After-Hours Session
Gainers Tesla Inc (NASDAQ: TSLA) shares are up 7% after reporting second-quarter deliveries of 95,200, beating analyst estimates. ... 
Tags Trading Ideas TSLA Market News
From Benzinga
BioTime Conducts Sale of Shares in OncoCyte Corporation
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of the sale of 2,250,000 shares of... 
From Business Wire News Releases
BioTime Announces Appointment of General Counsel
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as... 
From Business Wire News Releases
BioTime (BTX) Q1 2019 Earnings Call Transcript
BTX earnings call for the period ending March 31, 2019. 
Tags BTX Market News
From Motley Fool
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019... 
From Business Wire News Releases
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, reported financial and operating results for the first quarter... 
From Business Wire News Releases
The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stock To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags AMRX ELOX MLNT
From Benzinga
BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent... 
From Business Wire News Releases
BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating... 
From Business Wire News Releases
The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags Top Stories ADAP AGIO
From Benzinga
BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that updated results from a Phase I/IIa clinical study of its lead... 
From Business Wire News Releases
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks staged a recovery this week after being in the red in the previous two weeks. 
Tags Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV)'s psoriasis ... 
Tags ORTX Benzinga RHHBY
From Benzinga
BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of... 
From Business Wire News Releases
BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead... 
From Business Wire News Releases
New Research Coverage Highlights BioMarin Pharmaceutical, EnLink Midstream, GCI Liberty, Vistra Energy, BioTime, and Karyopharm Therapeutics — Consolidated Revenues, Company Growth, and Expectations f
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BioMarin Pharmaceutical Inc.... 
From GlobeNewswire News Releases
BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting... 
From Business Wire News Releases
The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamas Opioid Overdose Drug NDA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags Trading Ideas MTNB RMED
From Benzinga
BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended... 
From Business Wire News Releases
The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags XBI NEOS BTX
From Benzinga
BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
BIOTIME ANNOUNCES CLOSING OF ACQUISITION OF ASTERIAS BIOTHERAPEUTICS CREATING LEADING CELL THERAPY COMPANY 
From Business Wire News Releases
BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial... 
From Business Wire News Releases
BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product... 
From Business Wire News Releases
BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate,... 
From GlobeNewswire News Releases
Consolidated Research: 2019 Summary Expectations for Walmart, W.R. Grace, BioTime, Genesee & Wyoming, Northrop Grumman, and Versum Materials — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Walmart Inc. (NYSE:WMT),... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.